 Liyen Loh
Concepts (259)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mucosal-Associated Invariant T Cells | 13 | 2025 | 38 | 3.340 |
Why?
| | CD8-Positive T-Lymphocytes | 20 | 2023 | 923 | 2.030 |
Why?
| | Simian Acquired Immunodeficiency Syndrome | 13 | 2014 | 92 | 1.680 |
Why?
| | Simian Immunodeficiency Virus | 12 | 2014 | 93 | 1.640 |
Why?
| | Influenza, Human | 15 | 2024 | 624 | 1.480 |
Why?
| | Influenza A virus | 10 | 2022 | 119 | 1.360 |
Why?
| | Killer Cells, Natural | 7 | 2024 | 481 | 1.290 |
Why?
| | Immunity, Innate | 5 | 2024 | 835 | 0.940 |
Why?
| | Influenza A Virus, H7N9 Subtype | 5 | 2018 | 5 | 0.870 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 8 | 2025 | 920 | 0.870 |
Why?
| | Th17 Cells | 1 | 2025 | 102 | 0.830 |
Why?
| | Leukocytes, Mononuclear | 7 | 2022 | 574 | 0.790 |
Why?
| | Colon | 1 | 2025 | 309 | 0.730 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 4 | 2023 | 334 | 0.730 |
Why?
| | Alleles | 2 | 2024 | 896 | 0.710 |
Why?
| | Colitis | 1 | 2025 | 281 | 0.710 |
Why?
| | Coculture Techniques | 2 | 2020 | 247 | 0.690 |
Why?
| | Epitopes, T-Lymphocyte | 7 | 2022 | 174 | 0.670 |
Why?
| | Gene Products, gag | 6 | 2012 | 38 | 0.670 |
Why?
| | Intestinal Mucosa | 1 | 2025 | 675 | 0.590 |
Why?
| | Alveolar Epithelial Cells | 1 | 2020 | 121 | 0.570 |
Why?
| | Thymus Gland | 5 | 2024 | 312 | 0.520 |
Why?
| | Phenotype | 3 | 2024 | 3170 | 0.510 |
Why?
| | Immunologic Memory | 7 | 2020 | 368 | 0.460 |
Why?
| | Immunity, Mucosal | 1 | 2016 | 98 | 0.450 |
Why?
| | Macaca nemestrina | 13 | 2014 | 29 | 0.450 |
Why?
| | Interleukin-18 | 1 | 2016 | 234 | 0.440 |
Why?
| | T-Lymphocyte Subsets | 5 | 2024 | 420 | 0.440 |
Why?
| | HLA-A24 Antigen | 2 | 2024 | 5 | 0.390 |
Why?
| | Cytokines | 6 | 2025 | 2069 | 0.370 |
Why?
| | Spirometry | 5 | 2025 | 233 | 0.370 |
Why?
| | Histocompatibility Antigens Class I | 5 | 2024 | 202 | 0.360 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 2010 | 177 | 0.340 |
Why?
| | Australia | 5 | 2024 | 291 | 0.340 |
Why?
| | Pneumonia, Viral | 1 | 2016 | 391 | 0.330 |
Why?
| | Natural Killer T-Cells | 2 | 2022 | 71 | 0.330 |
Why?
| | Immunophenotyping | 4 | 2020 | 322 | 0.310 |
Why?
| | Cell Differentiation | 4 | 2024 | 2050 | 0.310 |
Why?
| | Immunity, Cellular | 3 | 2018 | 274 | 0.290 |
Why?
| | Single-Cell Analysis | 2 | 2024 | 361 | 0.290 |
Why?
| | Mice, Inbred C57BL | 7 | 2025 | 5993 | 0.290 |
Why?
| | Forced Expiratory Volume | 5 | 2025 | 450 | 0.290 |
Why?
| | T-Lymphocytes, Helper-Inducer | 2 | 2021 | 132 | 0.290 |
Why?
| | Genes, gag | 1 | 2008 | 4 | 0.280 |
Why?
| | CD4-Positive T-Lymphocytes | 7 | 2021 | 1146 | 0.280 |
Why?
| | Granzymes | 2 | 2020 | 49 | 0.270 |
Why?
| | Humans | 48 | 2025 | 145783 | 0.270 |
Why?
| | Animals | 25 | 2025 | 38102 | 0.260 |
Why?
| | Lymphocyte Activation | 5 | 2020 | 1133 | 0.260 |
Why?
| | Viruses | 2 | 2020 | 166 | 0.260 |
Why?
| | Vital Capacity | 4 | 2025 | 292 | 0.260 |
Why?
| | Interferon-gamma | 4 | 2020 | 784 | 0.250 |
Why?
| | Receptors, Antigen, T-Cell | 5 | 2024 | 673 | 0.250 |
Why?
| | Fetus | 3 | 2024 | 804 | 0.250 |
Why?
| | T-Lymphocytes | 5 | 2024 | 1998 | 0.250 |
Why?
| | Mutation | 6 | 2014 | 4090 | 0.240 |
Why?
| | Cell Communication | 2 | 2020 | 327 | 0.240 |
Why?
| | Immunotherapy | 5 | 2024 | 668 | 0.230 |
Why?
| | Monocytes | 2 | 2020 | 539 | 0.230 |
Why?
| | Oceania | 1 | 2024 | 5 | 0.220 |
Why?
| | Receptors, KIR3DL1 | 1 | 2024 | 20 | 0.210 |
Why?
| | Mice, Knockout | 4 | 2025 | 3130 | 0.210 |
Why?
| | Vaccination | 5 | 2021 | 1428 | 0.210 |
Why?
| | Blood | 2 | 2019 | 107 | 0.210 |
Why?
| | B-Lymphocytes | 2 | 2021 | 872 | 0.200 |
Why?
| | Bronchiectasis | 1 | 2025 | 115 | 0.200 |
Why?
| | Anus Neoplasms | 1 | 2024 | 32 | 0.200 |
Why?
| | Bronchodilator Agents | 2 | 2023 | 187 | 0.200 |
Why?
| | Mice | 8 | 2025 | 18356 | 0.200 |
Why?
| | Aging | 3 | 2020 | 1973 | 0.200 |
Why?
| | Viral Load | 4 | 2024 | 526 | 0.200 |
Why?
| | Lung Diseases, Obstructive | 1 | 2023 | 43 | 0.190 |
Why?
| | Virus Replication | 4 | 2024 | 521 | 0.190 |
Why?
| | Lymphocytes | 1 | 2024 | 376 | 0.190 |
Why?
| | Viremia | 3 | 2008 | 160 | 0.180 |
Why?
| | Orthomyxoviridae Infections | 2 | 2024 | 71 | 0.180 |
Why?
| | Rectal Neoplasms | 1 | 2024 | 159 | 0.180 |
Why?
| | Selection, Genetic | 1 | 2024 | 263 | 0.180 |
Why?
| | Cough | 1 | 2023 | 124 | 0.170 |
Why?
| | Influenza Vaccines | 3 | 2022 | 534 | 0.170 |
Why?
| | Hematologic Neoplasms | 1 | 2024 | 168 | 0.170 |
Why?
| | Airway Obstruction | 1 | 2023 | 153 | 0.170 |
Why?
| | Disease Models, Animal | 5 | 2025 | 4568 | 0.170 |
Why?
| | DNA, Viral | 2 | 2014 | 356 | 0.170 |
Why?
| | Forkhead Box Protein O1 | 1 | 2021 | 35 | 0.160 |
Why?
| | Immunodominant Epitopes | 1 | 2020 | 27 | 0.160 |
Why?
| | HLA-B27 Antigen | 1 | 2020 | 16 | 0.160 |
Why?
| | Cells, Cultured | 4 | 2021 | 4151 | 0.160 |
Why?
| | Artificial Intelligence | 1 | 2025 | 381 | 0.160 |
Why?
| | Lysosomal-Associated Membrane Protein 1 | 1 | 2020 | 12 | 0.160 |
Why?
| | Antibody Formation | 1 | 2021 | 288 | 0.150 |
Why?
| | Lymphocyte Subsets | 1 | 2020 | 78 | 0.150 |
Why?
| | Cellular Senescence | 2 | 2021 | 226 | 0.150 |
Why?
| | Genetic Variation | 1 | 2024 | 977 | 0.150 |
Why?
| | Proviruses | 1 | 2019 | 16 | 0.150 |
Why?
| | HLA-B37 Antigen | 1 | 2018 | 1 | 0.150 |
Why?
| | HLA-A1 Antigen | 1 | 2018 | 3 | 0.140 |
Why?
| | HTLV-I Infections | 1 | 2019 | 29 | 0.140 |
Why?
| | Lung | 5 | 2024 | 4116 | 0.140 |
Why?
| | Adult | 16 | 2025 | 40881 | 0.140 |
Why?
| | Human T-lymphotropic virus 1 | 1 | 2019 | 32 | 0.140 |
Why?
| | SAIDS Vaccines | 2 | 2009 | 4 | 0.140 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2019 | 56 | 0.140 |
Why?
| | Clonal Selection, Antigen-Mediated | 1 | 2018 | 5 | 0.140 |
Why?
| | Mucous Membrane | 2 | 2022 | 128 | 0.140 |
Why?
| | Antibodies, Viral | 4 | 2018 | 674 | 0.130 |
Why?
| | Aged | 11 | 2025 | 26217 | 0.130 |
Why?
| | Respiratory System | 1 | 2019 | 150 | 0.130 |
Why?
| | Extracellular Vesicles | 1 | 2020 | 171 | 0.130 |
Why?
| | Virus Diseases | 1 | 2020 | 216 | 0.130 |
Why?
| | Cross Reactions | 2 | 2014 | 130 | 0.130 |
Why?
| | Melanoma | 1 | 2024 | 762 | 0.130 |
Why?
| | Hypersensitivity | 1 | 2020 | 254 | 0.130 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily B | 1 | 2016 | 9 | 0.120 |
Why?
| | Host-Pathogen Interactions | 1 | 2020 | 361 | 0.120 |
Why?
| | Skin Neoplasms | 1 | 2024 | 853 | 0.120 |
Why?
| | HIV Infections | 4 | 2014 | 3195 | 0.120 |
Why?
| | Survival Analysis | 2 | 2018 | 1378 | 0.120 |
Why?
| | A549 Cells | 1 | 2016 | 75 | 0.120 |
Why?
| | Female | 19 | 2025 | 79045 | 0.120 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 979 | 0.120 |
Why?
| | Male | 18 | 2025 | 73011 | 0.120 |
Why?
| | Middle Aged | 11 | 2025 | 36309 | 0.120 |
Why?
| | Minor Histocompatibility Antigens | 3 | 2022 | 47 | 0.120 |
Why?
| | RNA, Viral | 2 | 2012 | 693 | 0.120 |
Why?
| | Inflammation | 2 | 2025 | 2884 | 0.120 |
Why?
| | AIDS Vaccines | 3 | 2010 | 53 | 0.110 |
Why?
| | Escherichia coli | 1 | 2020 | 835 | 0.110 |
Why?
| | Influenza A Virus, H1N1 Subtype | 2 | 2014 | 159 | 0.110 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2020 | 1217 | 0.110 |
Why?
| | Tomography, X-Ray Computed | 1 | 2025 | 2770 | 0.110 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 1 | 2014 | 21 | 0.110 |
Why?
| | HIV Antibodies | 1 | 2014 | 61 | 0.100 |
Why?
| | Multiple Myeloma | 1 | 2018 | 309 | 0.100 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2014 | 133 | 0.100 |
Why?
| | Poverty | 1 | 2017 | 529 | 0.100 |
Why?
| | Cohort Studies | 5 | 2025 | 6033 | 0.100 |
Why?
| | Gene Expression Regulation | 4 | 2018 | 2601 | 0.090 |
Why?
| | Cell Line, Tumor | 1 | 2020 | 3551 | 0.090 |
Why?
| | Genetic Engineering | 2 | 2009 | 88 | 0.090 |
Why?
| | Influenza B virus | 2 | 2022 | 47 | 0.090 |
Why?
| | Gene Expression | 1 | 2016 | 1478 | 0.080 |
Why?
| | Transcriptome | 1 | 2018 | 1042 | 0.080 |
Why?
| | Cardiovascular Diseases | 1 | 2023 | 2191 | 0.080 |
Why?
| | Albuterol | 2 | 2023 | 76 | 0.080 |
Why?
| | HIV-1 | 2 | 2014 | 908 | 0.080 |
Why?
| | Cross-Sectional Studies | 4 | 2023 | 5925 | 0.070 |
Why?
| | Chronic Disease | 2 | 2023 | 1812 | 0.070 |
Why?
| | HIV | 2 | 2009 | 251 | 0.070 |
Why?
| | Prevalence | 3 | 2023 | 2875 | 0.070 |
Why?
| | Adoptive Transfer | 2 | 2020 | 200 | 0.070 |
Why?
| | HLA-A Antigens | 2 | 2022 | 52 | 0.070 |
Why?
| | Replicon | 1 | 2008 | 12 | 0.070 |
Why?
| | Neoplasms | 1 | 2024 | 2913 | 0.070 |
Why?
| | Young Adult | 6 | 2021 | 14254 | 0.070 |
Why?
| | West Nile virus | 1 | 2008 | 41 | 0.070 |
Why?
| | Vaccines, Synthetic | 1 | 2008 | 137 | 0.060 |
Why?
| | Molecular Sequence Data | 2 | 2008 | 2883 | 0.060 |
Why?
| | Models, Biological | 1 | 2014 | 1764 | 0.060 |
Why?
| | Oligopeptides | 1 | 2008 | 267 | 0.060 |
Why?
| | Hemagglutinin Glycoproteins, Influenza Virus | 2 | 2018 | 29 | 0.060 |
Why?
| | Peptides | 3 | 2022 | 999 | 0.060 |
Why?
| | Polymerase Chain Reaction | 1 | 2008 | 1043 | 0.060 |
Why?
| | Acute Disease | 1 | 2008 | 1036 | 0.050 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2025 | 122 | 0.050 |
Why?
| | Carboxylic Ester Hydrolases | 1 | 2024 | 24 | 0.050 |
Why?
| | Oleic Acid | 1 | 2024 | 40 | 0.050 |
Why?
| | Base Sequence | 1 | 2008 | 2171 | 0.050 |
Why?
| | Bronchi | 1 | 2025 | 263 | 0.050 |
Why?
| | ROC Curve | 1 | 2025 | 618 | 0.050 |
Why?
| | Occupations | 1 | 2023 | 51 | 0.050 |
Why?
| | Signal Transduction | 1 | 2016 | 5224 | 0.050 |
Why?
| | Immunoglobulins | 1 | 2023 | 163 | 0.050 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2024 | 139 | 0.050 |
Why?
| | Receptors, KIR | 1 | 2023 | 118 | 0.050 |
Why?
| | Amino Acid Sequence | 2 | 2021 | 2131 | 0.050 |
Why?
| | Risk Factors | 3 | 2023 | 10919 | 0.040 |
Why?
| | Quality of Life | 2 | 2025 | 3211 | 0.040 |
Why?
| | Gene Expression Profiling | 2 | 2020 | 1777 | 0.040 |
Why?
| | Cell Proliferation | 2 | 2020 | 2514 | 0.040 |
Why?
| | Fetal Development | 1 | 2024 | 298 | 0.040 |
Why?
| | Aged, 80 and over | 3 | 2021 | 8347 | 0.040 |
Why?
| | Ligands | 1 | 2023 | 668 | 0.040 |
Why?
| | Dyspnea | 1 | 2023 | 250 | 0.040 |
Why?
| | Thymocytes | 1 | 2020 | 33 | 0.040 |
Why?
| | Cost of Illness | 1 | 2023 | 324 | 0.040 |
Why?
| | Time Factors | 2 | 2010 | 7134 | 0.040 |
Why?
| | Hong Kong | 1 | 2020 | 7 | 0.040 |
Why?
| | Malaysia | 1 | 2020 | 15 | 0.040 |
Why?
| | Singapore | 1 | 2020 | 27 | 0.040 |
Why?
| | Haloperidol | 1 | 2020 | 32 | 0.040 |
Why?
| | Viral Plaque Assay | 1 | 2020 | 29 | 0.040 |
Why?
| | Respiratory Tract Infections | 1 | 2024 | 396 | 0.040 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2020 | 156 | 0.040 |
Why?
| | Gene Frequency | 1 | 2021 | 489 | 0.040 |
Why?
| | Dogs | 1 | 2021 | 478 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2024 | 735 | 0.040 |
Why?
| | Exudates and Transudates | 1 | 2019 | 12 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2021 | 421 | 0.040 |
Why?
| | Hospitalization | 2 | 2021 | 2461 | 0.040 |
Why?
| | Antigen Presentation | 1 | 2020 | 208 | 0.040 |
Why?
| | Nucleic Acid Amplification Techniques | 1 | 2018 | 39 | 0.040 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 193 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2020 | 501 | 0.030 |
Why?
| | Antibody-Producing Cells | 1 | 2018 | 29 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2020 | 442 | 0.030 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2018 | 43 | 0.030 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2018 | 28 | 0.030 |
Why?
| | Thalidomide | 1 | 2018 | 43 | 0.030 |
Why?
| | Vaccines, Inactivated | 1 | 2018 | 70 | 0.030 |
Why?
| | Cellular Microenvironment | 1 | 2018 | 94 | 0.030 |
Why?
| | Uterus | 1 | 2018 | 228 | 0.030 |
Why?
| | Phylogeny | 1 | 2021 | 917 | 0.030 |
Why?
| | HLA-DR Antigens | 1 | 2018 | 220 | 0.030 |
Why?
| | Allergens | 1 | 2020 | 386 | 0.030 |
Why?
| | Lymphoid Progenitor Cells | 1 | 2016 | 11 | 0.030 |
Why?
| | Antigens, CD1d | 1 | 2016 | 69 | 0.030 |
Why?
| | International Cooperation | 1 | 2017 | 197 | 0.030 |
Why?
| | Macrophages | 1 | 2024 | 1507 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2021 | 2191 | 0.030 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2018 | 266 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2019 | 1165 | 0.030 |
Why?
| | Receptors, KIR2DL1 | 1 | 2015 | 22 | 0.030 |
Why?
| | Respiratory Function Tests | 1 | 2017 | 544 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 2018 | 499 | 0.030 |
Why?
| | Neoplasm Proteins | 1 | 2018 | 442 | 0.030 |
Why?
| | Antigens, CD | 1 | 2018 | 558 | 0.030 |
Why?
| | Hemagglutination Tests | 1 | 2014 | 7 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2020 | 769 | 0.030 |
Why?
| | Smoking | 1 | 2021 | 1477 | 0.030 |
Why?
| | Pregnancy Trimester, Second | 1 | 2014 | 85 | 0.020 |
Why?
| | Likelihood Functions | 1 | 2014 | 138 | 0.020 |
Why?
| | Child | 2 | 2024 | 22740 | 0.020 |
Why?
| | Mitochondria | 1 | 2020 | 993 | 0.020 |
Why?
| | Pregnancy | 2 | 2018 | 7216 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 2020 | 1482 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2015 | 751 | 0.020 |
Why?
| | Prospective Studies | 1 | 2025 | 8078 | 0.020 |
Why?
| | HLA Antigens | 1 | 2014 | 240 | 0.020 |
Why?
| | Crystallography, X-Ray | 1 | 2014 | 486 | 0.020 |
Why?
| | RNA | 1 | 2018 | 912 | 0.020 |
Why?
| | Critical Illness | 1 | 2018 | 900 | 0.020 |
Why?
| | Prognosis | 1 | 2020 | 4330 | 0.020 |
Why?
| | Age Factors | 1 | 2017 | 3346 | 0.020 |
Why?
| | MicroRNAs | 1 | 2016 | 686 | 0.020 |
Why?
| | Receptors, OX40 | 1 | 2008 | 16 | 0.020 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2009 | 50 | 0.020 |
Why?
| | Fusion Proteins, gag-pol | 1 | 2008 | 2 | 0.020 |
Why?
| | Viral Vaccines | 1 | 2008 | 107 | 0.020 |
Why?
| | Random Allocation | 1 | 2008 | 365 | 0.020 |
Why?
| | Models, Animal | 1 | 2009 | 392 | 0.020 |
Why?
| | Blood Component Transfusion | 1 | 2008 | 102 | 0.020 |
Why?
| | Longevity | 1 | 2008 | 178 | 0.020 |
Why?
| | Cross-Over Studies | 1 | 2008 | 610 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2008 | 778 | 0.010 |
Why?
| | Biomarkers | 1 | 2016 | 4302 | 0.010 |
Why?
| | Cell Line | 1 | 2009 | 2823 | 0.010 |
Why?
| | Adolescent | 1 | 2019 | 22577 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2008 | 11794 | 0.010 |
Why?
|
|
Loh's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|